The proportion of participants with CSF amyloid or tau pathology in accordance with IWG-2 criteria (46%) in our study parallels findings based on Alzheimer's Disease Neuroimaging Initiative data.33 The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.